Three mammalian bombesin receptor subtypes have been characterized: the gastrin-releasing peptide receptor (GRP-R), the neuromedin B receptor (NMB-R), and bombesin receptor subtype 3 (BRS-3). In a previous report we identified four amino acids that are critical for high affinity binding of bombesin and gastrin-releasing peptide (GRP) to the GRP-R. These four amino acids are conserved in all species variants of the GRP-R and NMB-R which bind bombesin with high affinity, but they are diverged in BRS-3, the bombesin receptor subtype that binds bombesin with much lower affinity. Substituting these four divergent amino acids in BRS-3 for the conserved amino acids in either GRP-R or NMB-R increased the affinity of the mutated BRS-3 (4⌬BRS-3) for bombesin compared with wild-type BRS-3. We hypothesized that the same four amino acids might be critical for high affinity NMB binding to the NMB-R. In this study we confirm this hypothesis by showing that the affinity of NMB is increased in a mutant BRS-3 receptor (4⌬BRS-3) that contains these four substitutions resulting in an affinity that is close to the affinity of wild-type NMB-R for NMB. In contrast, these four amino acid substitutions in BRS-3 did not result in the formation of a high affinity binding site for the recently described non-peptide NMB-R antagonist PD168368.
muscle contractility, the modulation of neuronal excitability, and the growth regulation of both normal and neoplastic cells (5) . In the central nervous system, these peptides play an important role in regulating body temperature, metabolism, feeding, and behavior (6) . In vitro, GRP and/or bombesin stimulates the growth of murine Swiss 3T3 fibroblasts (7) and the human prostate cancer cell line PC-3 (8) . Rat-1 fibroblasts expressing a transfected NMB-R acquire a mitogenic response to NMB (9) . In vivo, bombesin stimulates the growth of a human pancreatic gastrinoma xenograft (10) . A neutralizing monoclonal antibody specific for the conserved carboxyl-terminal end of bombesin-like peptides inhibits the soft agar colony growth of some human small cell lung carcinoma cell lines in vitro and inhibits the growth of small cell lung carcinoma cell lines that form nude mouse xenografts in vivo (11) .
The biologic responses elicited by bombesin-like peptides in mammalian systems are mediated by high affinity binding of GRP and/or NMB to one or more of the three known mammalian bombesin receptor subtypes: the neuromedin B receptor (NMB-R, or bb1) (12, 13) , the gastrin-releasing peptide receptor (GRP-R, or bb2) (13) (14) (15) , and bombesin receptor subtype 3 (BRS-3, or bb3) (16, 17) . Although the three subtypes share about 50% amino acid sequence identity when their primary amino acid sequences are aligned to maximize identity, the three receptors are pharmacologically distinct. NMB-R binds bombesin and NMB with highest affinity (nanomolar range) and GRP with lower affinity (hundreds of nanomolar range). GRP-R binds bombesin and GRP with highest affinity (nanomolar range) and NMB with lower affinity (hundreds of nanomolar range). In contrast, BRS-3 binds none of the naturally occurring bombesin-like peptides (bombesin, GRP, or NMB) with an affinity higher than micromolar (18) , suggesting that the naturally occurring ligand for BRS-3 may be a mammalian bombesin-like peptide that remains to be elucidated.
In previous work, we initiated an assessment of the molecular and structural requirements for high affinity binding of bombesin and GRP to the GRP-R (19) . To identify candidate amino acid residues of importance for high affinity binding, we reasoned that: 1) many of the amino acid residues involved in binding would be found primarily in the three extracellular loops and seven transmembrane domains of the receptor because the ligand approaches the receptor from the extracellular space, and 2) some of the amino acids critical for high affinity binding would be conserved among all species variants of the bombesin receptors that bind peptide ligands with high affinity (GRP-R and NMB-R) but would diverge in BRS-3, a bombesin receptor subtype that binds none of the known naturally occurring bombesin peptides with high affinity. Using these criteria, four amino acids (Arg 288 , Gln 121 , Pro 199 , and Ala 308 ) were identified which, when changed in the GRP-R to resemble their counterpart in BRS-3, resulted in a loss of affinity for bombesin. To confirm the importance of these four amino acids for * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. were changed to resemble their counterpart in the GRP-R, thereby creating a mutant BRS-3 called 4⌬BRS-3. If these four amino acids are critical for high affinity binding, we predicted that 4⌬BRS-3 would bind bombesin and GRP with higher affinity than wildtype BRS-3, thereby showing a gain of function. Changing these four amino acids resulted in a roughly 100-fold increase in the affinity for bombesin and GRP, providing conclusive evidence for the importance of these residues in high affinity binding to the GRP-R.
Given the structural similarity between mammalian bombesin peptide ligands and their receptors, we hypothesized that some or all of these four amino acids conserved between GRP-R and NMB-R may be important for high affinity binding of NMB to the NMB-R. In this paper, we explore the importance of these four amino acids by creating a receptor structure that can bind NMB with high affinity. In addition, we compare the importance of these same four amino acids for high affinity binding of agonists with their importance in high affinity binding of a recently described non-peptide bombesin receptor antagonist, PD168368 (20) , which binds the NMB-R with an affinity in the nanomolar range.
EXPERIMENTAL PROCEDURES
Construction of Plasmids and Site-directed Mutagenesis-cDNA inserts for the rat NMB-R (12) and for human BRS-3 (17) were identical to those described previously except that a flag epitope tag was added to the 5Ј-end of human BRS-3. These cDNA fragments encoding the entire coding sequences of each receptor were cloned into the EcoRI site of pcDNA3 (Invitrogen, San Diego) or a modified version of pcD2 (21) . To generate point mutations in these cDNAs, we initially used the Chameleon TM double-stranded site-directed mutagenesis kit as suggested by the manufacturer (Stratagene, La Jolla, CA). In our hands, the Chameleon procedure generated an unacceptable number of random mutations. Therefore, we introduced subsequent amino acid substitutions in BRS-3 with the QuickChange TM kit (Stratagene) following the manufacturer's instructions, except that the DpnI digestion was incubated overnight. Nucleotide sequence analysis of the entire coding region of all receptor mutants was performed on an automated DNA sequencer (ABI 373, Applied Biosystems Inc, Foster City, CA) to verify the presence of the desired mutation sequence and to confirm that there were no unwanted amino acid sequence changes introduced during the mutagenesis procedure.
Cell Transfection-Balb 3T3 cells (American Type Culture Collection, Rockville, MD) were seeded in a 24-well plate at a density of 30,000 cells/well and grown overnight at 37°C in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) qualified fetal bovine serum. The following morning cells were transfected with 3 g of plasmid DNA and 18 g of LipofectAMINE in Opti-MEM I for 1 h at 37°C. At the end of the incubation period, the medium was replaced with Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum. 24 h after transfection, the cells were released from the 24-well plates by treatment with trypsin-EDTA and seeded at varying densities ranging from 100 to 10,000 cells/10-cm diameter dish (Falcon, Becton Dickinson). 48 h after transfection the cells were placed in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum, penicillin, streptomycin, and 800 g/ml G418, and selection continued for 10 -14 days. Clones were selected, expanded, and screened for binding to 125 I-[D-Tyr 6 ,␤Ala 11 ,Phe 13 ,Nle 14 ]bombesin (6 -14) , a synthetic bombesin-like peptide that binds all known bombesin receptor subtypes, including BRS-3, with high affinity (18) . Alternatively, transfected clones were screened for receptor expression by Northern blot analysis using established procedures (22) . Stable cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum, penicillin, streptomycin, and 300 g/ml G418. All reagents used in cell transfection are from Life Technologies, Inc.
Whole Cell Radioligand Binding Assays-Competitive binding assays were performed essentially as described previously (19) . Briefly, disaggregated transfected cells were incubated for 1 h at room temperature in 300 l of buffer containing 140 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 50 mM HEPES/NaOH (pH 7.4), 0.1% bovine serum albumin, and 0.1% bacitracin (Sigma), 10 (18) in the presence of the indicated concentration of unlabeled peptides. The cell concentration was adjusted from 0.1 to 4 ϫ 10 6 cells/ml to assure that no more than 10% of the total added counts of the radioligand bound. Bound tracer was then separated from unbound tracer by layering 100 l of the binding reaction on top of an oil phase (100 l, Nyosil-50, Willian Nye, Inc. New Bedford, MA) in a 0.4-ml microcentrifuge tube (PGC Scientific, Frederick, MD), and pelleting the cells through the oil by centrifugation in a Beckman Microfuge 12 centrifuge at 10,000 rpm for 3 min. The pelleted cells were rinsed twice with ice-cold 2% bovine serum albumin in phosphate-buffered saline, and the amount of radioactivity bound to the cells was measured in a Cobra II gamma counter (Packard, Downers Grove, IL). At 1 h the binding reaction was at equilibrium as indicated by a plateau in radioligand binding as a function of time (data not shown), and the tracer was not degraded measurably as determined by high performance chromatography of the radioligand from the binding reaction. Each point was measured in duplicate, and each experiment was replicated at least three times. K d and K i values represent the means Ϯ S.E.
Measurement of Inositol Phosphates-Balb 3T3 cells expressing a transfected receptor gene were stimulated with NMB and total phosphoinositides determined essentially as described (23) . Briefly, cells were seeded at 30,000 cells/well in a 24-well plate, and the following day the serum in the culture medium was reduced from 10% to 0.25% to induce a relatively quiescent cell population. 48 h after seeding the cells, fresh medium containing 0.25% serum and 3 Ci/ml myo-[2- 1 shows an alignment of the amino acid sequences of BRS-3, NMB-R, and GRP-R. Nine consensus differences in agonist-accessible domains were identified in a previous study (19) and are shown in bold letters. Among these, the four amino acids known to influence agonist binding to GRP-R are designated by an asterisk. Fig. 2 (Table I ). This quantitative similarity between K i and K d values for the two radioligands suggests that these two tracers are occupying similar if not identical binding pockets. The K i for NMB displacing 125 I-BRS-3 from the wild-type BRS-3 receptor is very high (3,450 Ϯ 610 nM) (Fig. 3 and Table I ); this K i value is decreased to 81 nM when two amino acids in BRS-3 are changed to resemble those found at the same location in NMB-R (BRS-3 R127Q, H294R) (2⌬BRS-3 in Fig. 3 and Table I ). When all four key amino acids are altered in BRS-3 (BRS-3 R127Q, H294R, S205P, S315A) to resemble their counterparts in NMB-R, there is an additional shift to high affinity (4⌬BRS-3; Fig. 3 and Table I ). To demonstrate that each amino acid in the set of four contributed to increased NMB affinity for 4⌬BRS-3, we added the point mutations sequentially to hBRS-3. As predicted, each additional substitution resulted in higher NMB affinity (Table I) .
The experiments above and the experiments examining GRP binding to its native receptor (19) 
FIG. 2. Serpentine diagram of the hBRS-3 receptor showing amino acid residues examined by site-directed mutagenesis.
The four amino acids implicated in high affinity binding of GRP to GRP-R, and NMB to NMB-R are shown as filled circles. The rectangles (R127Q, H294R) indicate amino acids that showed a major loss of affinity when altered in GRP-R to their counterpart in BRS-3; the ovals (S205P, S315A) designate residues where the loss of function was less severe (19) . mutant receptors was not detectable above background (Table  I , right column). Also as predicted, 125 I-[Tyr 0 ]NMB binding to 4⌬BRS-3 and to 3⌬BRS-3 (R127Q, H294R, S205P) was measurable. We were therefore able to establish K d values for NMB binding to these receptors (Table I , right column, and Fig. 4) . Remarkably, the K d for NMB binding to 4⌬BRS-3 is 9.3 nM, very close to the 3.0 nM value obtained for the wild-type NMB-R. We concluded that by altering four amino acids in BRS-3, we have restored most of the structural requirements for high affinity NMB binding.
To substantiate these results, we compared NMB-stimulated inositol phosphate hydrolysis mediated by wild-type NMB-R, 2⌬BRS-3, 4⌬BRS-3, and wild-type BRS-3. All four receptors retain the capacity to couple to heterotrimeric GTP-binding proteins, activating phospholipase C which in turn catalyzes inositol phosphate hydrolysis (Fig. 5) . The EC 50 values for the four receptors are very different, with much lower concentrations of NMB needed to obtain 50% maximal inositol phosphate hydrolysis when the NMB-R is studied (27 nM; Fig. 5 ) than is needed for BRS-3 (2,850 nM; Fig. 5 ). As expected, 4⌬BRS-3 has an EC 50 for inositol phosphate hydrolysis closer to the NMB-R (313 nM; Fig. 5 ), whereas 2⌬BRS-3 (1,042 nM; Fig. 5 ) is shifted toward the value obtained for wild-type BRS-3 (2,850 nM; Fig.  5 ). These data are summarized in Table II , demonstrating that the rank order of potency for NMB-stimulated inositol phos- phate hydrolysis mediated by these four receptors mirrors the affinity of the four receptors for NMB. In addition, these results indicate that all four receptors retain the capacity to couple with appropriate G-proteins and stimulate appropriate downstream effector cascades.
Recently, a new class of potent neuromedin B receptor antagonists was reported. These compounds show a higher affinity for NMB-R than GRP-R (20) . To determine if the same structural requirements are needed for binding NMB and the NMB-R antagonist, we measured the K i values for unlabeled antagonist displacing the binding of 125 I-D-Tyr 0 -NMB and 125 I-BRS-3 (Fig. 6 ). Note that the K i for the antagonist PD168368 is high affinity for the NMB-R and very low affinity for BRS-3 ( Fig. 6 and Table III) . If the structural requirements for high affinity NMB and PD168368 binding were very similar, it was predicted that the K i for PD168368 binding to 4⌬BRS-3 would be shifted away from the value obtained for wild-type BRS-3 and toward the higher affinity value observed in the wild-type NMB-R. In fact, the ligand displacement curves for PD168368 displacing 125 I-BRS-3 binding to BRS-3 and 4⌬BRS-3 are nearly superimposable (Fig. 6 ). These data indicate that the structural requirements for binding the NMB-R antagonist PD168368 and NMB may be overlapping but are clearly distinct.
DISCUSSION
In this work, we show that four conserved amino acids known to be important for high affinity binding of GRP and bombesin to the GRP-R are also critical for high affinity NMB binding to NMB-R. Altering these four amino acids in BRS-3, a low affinity bombesin receptor, to their counterpart positions in NMB-R resulted in a several hundredfold increase in affinity of the BRS-3 mutant (4⌬BRS-3) for NMB. The affinity for NMB binding to 4⌬BRS-3 (9.3 nM) approaches its affinity for the wild-type NMB-R (3.0 nM). A conceptually similar study of opioid receptors was reported recently (25) where amino acids that directly influenced high affinity opioid agonist binding were identified. In both this study and the opioid receptor study, correlation between amino acid changes and gain of function (increase in affinity) provide persuasive evidence that the amino acids under examination are a specific component of the structural requirement for high affinity binding. Studies that argue a direct role for specific amino acids in agonist binding based on loss of affinity alone are less compelling because a loss of function could result from a number of changes in the receptor (e.g. protein stability, membrane trafficking, proper folding) other than formation of the high affinity ligand binding pocket.
In a similar study of GRP binding to 4⌬BRS-3, the affinity for binding was improved over the affinity observed in wildtype BRS-3 (370 nM, 4⌬BRS-3; Ͼ10,000 nM, wild-type BRS-3 (19)) but was not restored to a value approaching the affinity of the wild-type GRP-R for GRP (3.5 nM (26)). Comparing the results of GRP and NMB binding to 4⌬BRS-3, it appears that the four amino acid substitutions in BRS-3 result in a binding pocket that more closely approximates the high affinity NMB binding site than the GRP binding site. This difference points to the existence of additional residues in BRS-3 that need to be altered to provide the structural requirements for high affinity binding of GRP. We speculate that amino acids that provide the structural requirements for selective high affinity binding of GRP to GRP-R may be consensus differences in the GRP-R, NMB-R, and BRS-3 found in the extracellular loops and transmembrane domains. Future site-directed mutagenesis experiments changing additional amino acids in 4⌬BRS-3 to resemble their counterparts in GRP-R will be needed to test this hypothesis.
Although 4⌬BRS-3 shows high affinity for NMB, the four amino acid substitutions do not result in high affinity binding of the non-peptide NMB-R antagonist PD168368. This result is unexpected because the strategy used to design PD168368 (20) involved: 1) defining the minimum active fragment of NMB agonist peptide; 2) identifying the three amino acids in NMB in this minimum fragment which were most crucial for binding; and 3) appending the side chains of these three most important amino acids onto a small molecule template. Clearly, this strategy for antagonist design relies heavily on incorporating structural features critical for NMB agonist binding to NMB-R, and it would be expected that sequence changes in BRS-3 which improve affinity for NMB would be likely to improve affinity for PD168368. However, we observed a very different result: 4⌬BRS-3 has a ligand displacement curve for increasing concentrations of PD168368 which is indistinguishable from BRS-3 shifted to more than 100-fold lower affinity than NMB-R. This suggests that PD168368 and NMB have overlapping but distinct structural requirements for high affinity binding. Other investigators have compared the binding sites for peptide agonists and non-peptide antagonists using several other G-protein-coupled peptide receptors, including the neurokinin 1 receptor (substance P receptor) (27) (28) (29) , the cholecystokinin B/gastrin receptor (30, 31) , and the angiotensin 1 receptor (32) . In all three receptors, each of the six studies concluded that the binding sites for non-peptide antagonists were distinct from natural peptide agonists. However, it should be noted that for these three receptors, the antagonists were obtained by random screening of compounds rather than by designing the antagonist based on known structural features of the peptide agonist shown to be essential for high affinity binding.
The binding constant of 4⌬BRS-3 for NMB is only 3-fold lower than in NMB-R, indicating that the four amino acids changed in 4⌬BRS-3 may provide much of the structural requirements for high affinity NMB binding. If some or all these four amino acids are contact points in the binding pocket, it may be possible to create a NMB agonist binding pocket in a heterologous G-protein-coupled receptor outside the bombesin receptor subfamily by making the same changes in the heterologous receptor which were made in 4⌬BRS-3. The ability to create an agonist binding site on a heterologous G-proteincoupled receptor would be useful in studying the function and signal transduction pathways of some of the numerous "orphan" G-protein-coupled receptors where no agonist is known. Additional studies will be needed to determine if these four amino acids are both necessary and sufficient for high affinity NMB binding to receptors outside the bombesin subfamily of G-protein-coupled receptors.
